Houlihan Lokey Advises Grünenthal

Houlihan Lokey is pleased to announce that Grünenthal GmbH has signed a new €500 million revolving credit facility. The transaction signed and closed in March 2023.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, it has a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Its purpose is to change lives for the better—and innovation is its passion. The company is focusing all of its activities and efforts on working towards its vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the US. Its products are available in approximately 100 countries. In 2022, Grünenthal employed around 4,400 people. In 2022, the company achieved stand-alone sales and adjusted EBITDA of approximately €1.7 billion and €438 million, respectively.

Houlihan Lokey served as the exclusive financial advisor to Grünenthal.

RELATED: Healthcare, Capital Markets